Febrile Neutropenia

More documents

Recommendations

Info

Patient-related and other risk factors for FN Age > 65 – Twice as likely to experience febrile neutropenia 1 – Prophylactic G-CSF G should be used in all elderly patients receiving myelotoxic chemotherapy 2 Other factors – Advanced disease stage – Previous episode of FN – Lack of G-CSF G use 4( & 8$ & Aapro et al, 2006
Role of nurses in evaluating patient risk Assess the FN risk of planned chemotherapy regimen Evaluate presence of individual patient risk factors Evaluate overall risk !$
Page 1 and 2: Febrile Neutropenia An ‘A-Z’ of
Page 3 and 4: Grading neutropenia !) * +
Page 6 and 7: Clinical presentation of infection
Page 8 and 9: Impact on chemotherapy delivery: Do
Page 10 and 11: Summary Neutropenia is a common
Page 12 and 13: Risk factors for FN Treatmentrelate
Page 16 and 17: Granulocyte colony-stimulating fact
Page 18 and 19: Side effects of G-CSFsG Mild/mode
Page 20 and 21: Febrile neutropenia Managing febril
Page 22 and 23: The impact of infection in patients
Page 24 and 25: Vital signs of SIRS Two or more of
Page 26 and 27: Clinical pathway to manage neutrope
Page 28 and 29: The goal is to minimise risk of inf
Page 30 and 31: Patient and family education: Focus
Page 32: Summary Febrile Neutropenia is

Febrile Neutropenia

Create successful ePaper yourself

Delete template?

Save as template?